Eagle IP attended the Hong Kong MedTech Innovation World Cup, a major international event showcasing cutting-edge medical technology innovations, startups, and industry leaders in March 2025.

Our Principals Ms. Jennifer Che and Ms. Yolanda Wang served as judges at a multiday pitch competition that will be occurring during the event. As a leading intellectual property firm in Hong Kong, Eagle IP is participating to engage with MedTech innovators, investors, and industry professionals. The event provides an excellent platform for the team to connect with companies developing novel medical devices, diagnostics, digital health solutions, and other healthcare technologies, while offering expert insights on IP protection and commercialization strategies in Asia.

我們過去活動

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Eagle IP’s Jennifer Che to Attend LSPN North America Spring 2026 in Boston

2026年4月29日

Pauli Wong to Share IP Strategy Insights at HKLSS Entrepreneurship Series 2026

2026年4月25日

Eagle IP and HKSTP Host AIPLA Women in IP Global Networking Event

2026年4月16日

Recommended Insights

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
閱讀更多 >

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

2020年10月28日
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]
閱讀更多 >

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

2025年9月4日
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]
閱讀更多 >

Miss the 12-month Filing Deadline? China Finally Allows Patent Applicants to Restore, Add, or Correct a Priority Claim

2024年4月15日
Three major 'remedial’ systems taken from the PCT Regulations have been introduced in the third revision of the Implementation Regulations of the Chinese Patent Law in 2023 (hereinafter referred to as the "Implementation Regulations"). We previously discussed one of these remedial systems, Incorporation by Reference based on Rule 45 of the Implementation Regulations, which allows […]
閱讀更多 >
Top crossarrow-right